• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 10-K/A filed by Amedisys Inc

    2/27/25 9:28:35 PM ET
    $AMED
    Medical/Nursing Services
    Health Care
    Get the next $AMED alert in real time by email
    amed-20241231
    truetrue2024FY000089626212/31iso4217:USDxbrli:shares00008962622024-01-012024-12-3100008962622024-06-2800008962622025-02-21

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 10-K/A
    (Amendment No. 1)
    (Mark One)
    ☒    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended: December 31, 2024
    OR
    ☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from                      to                     
    Commission File Number: 0-24260
    amedisysa02.jpg
    AMEDISYS, INC.
    (Exact Name of Registrant as Specified in its Charter)
    Delaware11-3131700
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)
    3854 American Way, Suite A, Baton Rouge, LA 70816
    (Address of principal executive offices, including zip code)
    (225) 292-2031 or (800) 467-2662
    (Registrant’s telephone number, including area code)
    Securities registered pursuant to Section 12(b) of the Act:

    Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
    Common Stock, par value $0.001 per shareAMEDThe NASDAQ Global Select Market
    Securities registered pursuant to Section 12(g) of the Act: None
    Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☑    No  ☐
    Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☑
    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑    No  ☐
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑    No  ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☑Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
    Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑
    If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  ☐
    Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No  ☑
    The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, based on the last sale price as quoted by the NASDAQ Global Select Market on June 28, 2024 (the last business day of the registrant’s most recently completed second fiscal quarter) was $3.0 billion. For purposes of this determination, shares beneficially owned by executive officers, directors and ten percent stockholders have been excluded, which does not constitute a determination that such persons are affiliates.
    As of February 21, 2025, the registrant had 32,810,291 shares of Common Stock outstanding.
    DOCUMENTS INCORPORATED BY REFERENCE
    Portions of the registrant’s definitive Proxy Statement for its 2025 Annual Meeting of Stockholders (the “2025 Proxy Statement”) are incorporated by reference into Part II – “Securities Authorized For Issuance Under Equity Compensation Plans” and Part III of this Form 10-K, or, in the event the registrant does not prepare and file such 2025 Proxy Statement, will be provided instead by an amendment to this report containing the applicable disclosures within 120 days after the end of the fiscal year covered by this report. With the exception of those portions which are specifically incorporated by reference in this report, any such Proxy Statement is not deemed to be filed or incorporated by reference as part of this report.




    EXPLANATORY NOTE

    This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 originally filed on February 27, 2025 (the “Original Filing”) by Amedisys, Inc. (the “Company,” “we,” “our,” or “us”). We are filing this Amendment solely to correct the Original Filing’s cover page to reflect the correct number of the Company’s outstanding shares of common stock as of February 21, 2025, which was 32,810,291 shares of common stock, $0.01 par value.
    In accordance with Rules 12b-15 and 13a-14 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we have also amended Part IV, Item 15 of Form 10-K to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from our principal executive officer and principal financial officer. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.
    Except as described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing.




    PART IV

    ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
    The exhibits marked with the cross symbol (†) are filed with this Form 10-K/A.
    Exhibit
    Number
    Document DescriptionReport or Registration StatementSEC File or
    Registration
    Number
    Exhibit
    or Other
    Reference
    †31.1
    Certification of Richard Ashworth, Chief Executive Officer (principal executive officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    †31.2
    Certification of Scott G. Ginn, Chief Operating Officer, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
    101Interactive Data Files for the Registrant's Form 10-K for the period ended December 31, 2024, formatted in Inline XBRL
    104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)



    SIGNATURES
    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
    AMEDISYS, INC.
    By:
    /S/    RICHARD ASHWORTH        
    Richard Ashworth,
    President and Chief Executive Officer
    Date: February 27, 2025

    Get the next $AMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMED

    DatePrice TargetRatingAnalyst
    7/29/2024$101.00Buy → Hold
    Deutsche Bank
    7/1/2024Outperform → Mkt Perform
    William Blair
    6/7/2023$97.00Buy → Hold
    Truist
    4/21/2023$87.00Neutral
    Cantor Fitzgerald
    3/13/2023$93.00Equal Weight
    Barclays
    10/27/2022Outperform → Mkt Perform
    Raymond James
    8/2/2022$145.00 → $95.00Neutral → Sell
    UBS
    6/29/2022$128.00Hold
    Stifel
    More analyst ratings

    $AMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amedisys downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00

      7/29/24 7:29:37 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by William Blair

      William Blair downgraded Amedisys from Outperform to Mkt Perform

      7/1/24 7:29:43 AM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys downgraded by Truist with a new price target

      Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00

      6/7/23 9:03:46 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amedisys Reports First Quarter 2025 Financial Results

      BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2025. Three-Month Periods Ended March 31, 2025 and 2024 Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 milli

      4/23/25 4:45:43 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year End 2024 Financial Results

      BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, 2024 and 2023 Net service revenue increased $27.3 million to $598.1 million compared to $570.8 million in 2023.Net loss attributable to Amedisys, Inc. of $20.4 million, which is inclusive of merger-related expenses totaling $17.4 million ($15.9 million, net of tax) and a non-cash goodwill and other intangibles impairment charge totaling $48.4 million ($38.4 million, net of noncontrolling interest and tax) compared to net income attributable to Amedisys, Inc. of $19.3 milli

      2/26/25 4:30:12 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Honors 47 Employees With Annual Spirit of Excellence Award

      BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are privileged to have exceptional clinicians who consistently exceed expectations, and it is a profound honor to recognize their incredible commitment." Each year, the company honors Home

      2/3/25 6:30:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Amedisys Reports Second Quarter 2024 Financial Results

      BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa

      7/24/24 4:30:52 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports First Quarter 2024 Financial Results

      BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o

      4/24/24 4:45:46 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results

      BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s

      2/21/24 4:30:11 PM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Guidroz Allyson covered exercise/tax liability with 171 shares, decreasing direct ownership by 2% to 7,943 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      6/3/25 8:18:53 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Guidroz Allyson sold $35,904 worth of shares (374 units at $96.00), decreasing direct ownership by 4% to 8,114 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/9/25 4:05:58 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Guidroz Allyson covered exercise/tax liability with 273 shares, decreasing direct ownership by 3% to 8,488 units (SEC Form 4)

      4 - AMEDISYS INC (0000896262) (Issuer)

      5/6/25 8:24:14 PM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/13/24 4:58:48 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/12/24 5:24:28 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by Amedisys Inc (Amendment)

      SC 13G/A - AMEDISYS INC (0000896262) (Subject)

      2/8/24 10:18:47 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    SEC Filings

    See more
    • SEC Form 8-K filed by Amedisys Inc

      8-K - AMEDISYS INC (0000896262) (Filer)

      5/1/25 5:00:16 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form 10-K/A filed by Amedisys Inc

      10-K/A - AMEDISYS INC (0000896262) (Filer)

      4/29/25 4:12:39 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Amedisys Inc

      10-Q - AMEDISYS INC (0000896262) (Filer)

      4/24/25 8:02:23 AM ET
      $AMED
      Medical/Nursing Services
      Health Care

    $AMED
    Financials

    Live finance-specific insights

    See more
    • AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

      BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million

      5/3/23 4:31:00 PM ET
      $AMED
      Medical/Nursing Services
      Health Care
    • Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

      All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo

      5/3/23 4:30:00 PM ET
      $AMED
      $OPCH
      Medical/Nursing Services
      Health Care
    • Amedisys Announces First Quarter 2023 Earnings Release and Conference Call Date

      BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th

      4/20/23 8:00:00 AM ET
      $AMED
      Medical/Nursing Services
      Health Care